title: Who wins the race of predicting chemoradiation-induced esophagitis? Is there anyone else to join the competition? In response to Tang et al.
authors.affiliation: Division of Hematology/Oncology, University of Kansas Medical Center, Fairway, United States. Electronic address: tkomiya@kumc.edu.
authors.forename: Takefumi
authors.initials: T
authors.lastname: Komiya
authors.affiliation: Department of Biostatistics, University of Kansas Medical Center, Kansas City, United States. Electronic address: spalla@kumc.edu.
authors.forename: Shana L
authors.initials: SL
authors.lastname: Palla
mesh_terms: D000210:Acute-Phase Reaction; D002289:Carcinoma, Non-Small-Cell Lung / Q000532:radiotherapy*; D004941:Esophagitis / Q000209:etiology*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000532:radiotherapy*; D008297:Male; D011832:Radiation Injuries / Q000209:etiology*